ClinicalTrials.gov

History of Changes for Study: NCT03071081
Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects
Latest version (submitted September 19, 2018) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 28, 2017 None (earliest Version on record)
2 May 22, 2017 Study Status and Contacts/Locations
3 July 6, 2017 Recruitment Status, Study Status and Contacts/Locations
4 September 19, 2018 Study Design and Study Status
Comparison Format:

Scroll up to access the controls

Study NCT03071081
Submitted Date:  February 28, 2017 (v1)

Open or close this module Study Identification
Unique Protocol ID: TOP1288-TV-03
Brief Title: Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects
Official Title: A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TOP1288 Oral Single Ascending and Multiple Doses in Healthy Volunteers
Secondary IDs:
Open or close this module Study Status
Record Verification: February 2017
Overall Status: Recruiting
Study Start: February 8, 2017
Primary Completion: June 3, 2017 [Anticipated]
Study Completion: June 3, 2017 [Anticipated]
First Submitted: February 20, 2017
First Submitted that
Met QC Criteria:
February 28, 2017
First Posted: March 6, 2017 [Actual]
Last Update Submitted that
Met QC Criteria:
February 28, 2017
Last Update Posted: March 6, 2017 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Topivert Pharma Ltd
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This study evaluates the safety and tolerability of TOP1288 oral single ascending and multiple doses in healthy subjects.
Detailed Description:
Open or close this module Conditions
Conditions: Ulcerative Colitis
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1
Interventional Study Model: Parallel Assignment
3 dose groups (2 arms per dose group)
Number of Arms: 6
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation: Randomized
Enrollment: 36 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: TOP1288 200mg BID
1 day dosing
Drug: TOP1288
Oral TOP1288
Placebo Comparator: Placebo to TOP1288 200mg BID
1 day dosing
Drug: Placebo to TOP1288
Oral placebo to TOP1288
Experimental: TOP1288 1g BID
1 day dosing
Drug: TOP1288
Oral TOP1288
Placebo Comparator: Placebo to TOP1288 1g BID
1 day dosing
Drug: Placebo to TOP1288
Oral placebo to TOP1288
Experimental: TOP1288 Xg (where X is <=1g) BID
7 days dosing
Drug: TOP1288
Oral TOP1288
Placebo Comparator: Placebo to TOP1288 Xg
7 days dosing
Drug: Placebo to TOP1288
Oral placebo to TOP1288
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Safety (AEs)
[ Time Frame: To 7 days after last dose ]

As measured by adverse events
2. Safety (ECGs)
[ Time Frame: To 7 days after last dose ]

As measured by ECGs
3. Safety (vital signs)
[ Time Frame: To 7 days after last dose ]

As measured by vital signs
4. Safety (clinical lab tests)
[ Time Frame: To 7 days after last dose ]

As measured by clinical laboratory tests
Secondary Outcome Measures:
1. Pharmacokinetic profile Cmax
[ Time Frame: 0-48 hours ]

Observed maximum plasma concentration, taken directly from the individual concentration-time curve (Cmax)
2. Pharmacokinetic profile AUC
[ Time Frame: 0-48 hours ]

Area under the plasma concentration-curve (AUC)
3. Pharmacokinetic profile AUC0-12h
[ Time Frame: 0-12 hours ]

AUC from time zero to 12 h (AUC0-12h)
4. Pharmacokinetic profile AUC0-24h
[ Time Frame: 0-24 hours ]

AUC from time zero to 24 h (AUC0-24h)
5. Pharmacokinetic profile AUC0-t
[ Time Frame: 0-48 hours ]

AUC from time zero to the last measurable concentration (AUC0-t)
6. Pharmacokinetic profile Racc
[ Time Frame: 0-48 hours ]

Accumulation ratio of the AUC (Racc) (multiple dose part only)
7. Pharmacokinetic profile tmax
[ Time Frame: 0-48 hours ]

Time to reach maximum concentration, taken directly from the individual concentration-time curve (tmax)
8. Pharmacokinetic profile t½
[ Time Frame: 0-48 hours ]

Terminal half-life (t½)
9. Pharmacokinetic profile λz
[ Time Frame: 0-48 hours ]

Terminal elimination rate constant (λz)
10. Pharmacokinetic profile CL/F
[ Time Frame: 0-48 hours ]

Apparent total clearance from plasma after oral administration (CL/F)
11. Pharmacokinetic profile Vz/F
[ Time Frame: 0-48 hours ]

Volume of distribution of the absorbed fraction (Vz/F)
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age: 55 Years
Sex: Male
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria:

  1. Subject is a healthy male, aged between 18 and 55 years of age (inclusive) at Screening.
  2. Subject has a body mass index (BMI) of between 18.0 and 29.9 kg/m2 (inclusive), with a body weight of at least 50 kg at Screening.
  3. Subject is in good physical and mental health in the opinion of the Investigator.
  4. Subject has clinical laboratory test results within the reference ranges of the testing laboratory unless results outside the reference ranges are deemed not clinically significant by the Investigator at Screening and Day -1.
  5. Subject has a supine blood pressure and pulse rate within the normal range after 5 minutes' rest (systolic blood pressure: 90 to 140 mmHg, diastolic blood pressure: 40 to 90 mmHg, pulse rate: 40 to 90 beats per minute) at Screening and Day -1.
  6. Subjects must be willing to comply with the contraception restrictions of the protocol for this study.
  7. Subject has regular bowel opening of usually 1 motion per day of normal consistency.

Exclusion Criteria:

  1. Subject has participated in another study of an investigational medication (or a medical device) within the last 3 months or 5 half-lives of the investigational medication, whichever is longer, prior to the first day or dosing.
  2. Subject has made a blood donation (> 400 mL) or had a comparable blood loss (> 350 mL) within the last 3 months prior to first administration of study drug.
  3. Subject tests positive for human immunodeficiency virus (HIV)-1/2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies at Screening.
  4. Subject has a history of alcohol and/or drug abuse.
  5. Subject has an alcohol consumption of more than 21 units of alcohol per week.
  6. Subject tests positive for alcohol and/or drugs (urine tests) at Screening or admission.
  7. Subject has received any prescription or non-prescription medications, including over-the-counter medications, nutraceuticals (e.g., St. John's Wort, ginseng, kava kava, Ginkgo biloba and melatonin), foods or beverages containing grapefruit and vitamin supplements within 14 days prior to admission (Day -1) or nutraceuticals containing caffeine- or xanthine-related substances within 72 hours prior to admission (Day -1). Foods or beverages containing Seville-type (sour) oranges, or poppy seeds are also excluded within this time period.
  8. The subject has a history of daily consumption of 5 or more cups of coffee or tea.
  9. Subject has a known hypersensitivity to any components of the study drug.
  10. Subject has any history of any clinically significant acute or chronic condition affecting the colon and/or rectum and/or anus, including haemorrhoids and irritable bowel syndrome, sufficient to cause symptoms and/or that in the judgement of the PI and the Sponsor's study Physician/Medical Monitor would interfere with the subject's participation in the study.
  11. Any findings on pre-dose endoscopy that in the PI's judgement would interfere with subject participation in the study.
  12. Subject has acute or chronic condition affecting GI motility such as constipation or diarrhoea that would, in the judgement of the PI and the Sponsor's study Physician/Medical Monitor, interfere with the subject's participation in the study
  13. Subject has cardiovascular or cerebrovascular disease, including hypertension, angina, ischaemic heart disease, transient ischaemic attacks, stroke and peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status.
  14. Subject has an active infection (e.g., sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalisation or requiring parenteral antibiotic treatment) within 6 weeks prior to study drug administration.
  15. Subject has a history of positive tuberculosis test or evidence of possible tuberculosis or latent tuberculosis infection at Screening (interferon gamma release assay testing) that cannot be attributed to a prior Bacillus Calmette-Guérin inoculation.
  16. Subject has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study.
  17. Subject has any of the following haematology values at Screening or Day -1:
    • Haemoglobin, < 13 g/dL.
    • Absolute neutrophil count < 1.5 x 109/L (< 1500/μL).
  18. Subject has a 12-lead electrocardiogram (ECG) with results considered to be potentially clinically significant, e.g., QTcF > 450 ms, bundle branch block, evidence of myocardial ischaemia, at Screening or Day -1.
  19. Subject has an abnormality in the ECG that, in the opinion of the Investigator, increases the risks associated with participating in the study.
  20. Subject has renal or liver impairment at Screening or Day -1, defined as:
    • Serum creatinine level ≥ 135 μmol/L, or
    • Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2 x upper limit of normal, or
    • Alkaline phosphate and/or bilirubin > 1.5 x upper limit of normal (an isolated bilirubin 1.5 x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin is < 35%).
  21. Subject has active neoplastic disease or history of any neoplastic disease within 5 years of Screening (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care).
  22. Subject has any other acute or chronic illness which, in the opinion of the Investigator or Sponsor's study Physician/Medical Monitor, could pose a threat or harm to the subject's participation in the study.
  23. The subject has used nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 2 weeks prior to admission to the study centre (Day -1).
Open or close this module Contacts/Locations
Central Contact Person: Muna Albayaty, MBChB, FFPM
Telephone: +44 (0) 189 561 4592
Study Officials: Muna Albayaty, MBChB, FFPM
Principal Investigator
Copenhagen Trial Unit, Center for Clinical Intervention Research
Locations: United Kingdom
PAREXEL Early Phase Clinical Unit
[Recruiting]
London, United Kingdom
Contact:Contact: Muna Albayaty, MBChB, FFPM
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services